IRIS, a randomised, double-blind, placebo-controlled trial of interleukin-6 receptor inhibition undergoing endovascular treatment in acute anterior circulation ischaemic stroke: study rationale and design
Administering tocilizumab within 24 hours of stroke as an adjunct to EVT may effectively reduce the infarct core volume for patients experiencing AIS with anterior circulation LVO, potentially improving functional outcomes in these patients.
Authors
- Jun Sun (ORCID: https://orcid.org/0000-0001-7465-3133)
- Benxiao Wang (ORCID: https://orcid.org/0000-0002-1217-8995)
- Chuanhui Li (ORCID: https://orcid.org/0000-0002-2808-1936)
- Xunming Ji (ORCID: https://orcid.org/0000-0003-0293-2744)
- Wenbo Zhao (ORCID: https://orcid.org/0000-0001-7808-0125)
- Xiangyang Feng (ORCID: https://orcid.org/0009-0006-3974-2003)
- Chuanjie Wu (ORCID: https://orcid.org/0000-0002-0494-416X)
- Zhengfei Ma (ORCID: https://orcid.org/0009-0006-0811-4776)
- Ning Wang (ORCID: https://orcid.org/0000-0002-1849-1747)
- Chaoqun Li (ORCID: https://orcid.org/0000-0001-8750-9237)
- Xuehong Chu
- Jianqiao Li (ORCID: https://orcid.org/0000-0001-6145-424X)
- Yifeng Liu (ORCID: https://orcid.org/0009-0009-0097-9873)
- Chen Zhou (ORCID: https://orcid.org/0000-0002-9705-4237)
Institutions
- Capital Medical University (CN)
- Nanyang Institute of Technology (CN)
- Suzhou Municipal Hospital (CN)
- Xintai People's Hospital (CN)
Publication Details
- Journal
- Stroke and Vascular Neurology
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1136/svn-2024-003574
- Citations
- 10
- Primary Topic
- Acute Ischemic Stroke Management
- Type
- article
- Field-Weighted Citation Impact
- 3.87
Funders
- National Natural Science Foundation of China